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Abstract
We developed a variant database for diabetes syndrome genes, using the Leiden Open Variation
Database platform, containing observed phenotypes matched to the genetic variations. We populated it with 628 published disease-associated variants (December 2016) for: WFS1 (n = 309),
CISD2 (n = 3), ALMS1 (n = 268), and SLC19A2 (n = 48) for Wolfram type 1, Wolfram type 2, Alström,
and Thiamine-responsive megaloblastic anemia syndromes, respectively; and included 23 previously unpublished novel germline variants in WFS1 and 17 variants in ALMS1. We then investigated genotype–phenotype relations for the WFS1 gene. The presence of biallelic loss-of-function
variants predicted Wolfram syndrome defined by insulin-dependent diabetes and optic atrophy,
with a sensitivity of 79% (95% CI 75%–83%) and specificity of 92% (83%–97%). The presence of
minor loss-of-function variants in WFS1 predicted isolated diabetes, isolated deafness, or isolated
congenital cataracts without development of the full syndrome (sensitivity 100% [93%–100%];
specificity 78% [73%–82%]). The ability to provide a prognostic prediction based on genotype will
lead to improvements in patient care and counseling. The development of the database as a repository for monogenic diabetes gene variants will allow prognostic predictions for other diabetes
syndromes as next-generation sequencing expands the repertoire of genotypes and phenotypes.
The database is publicly available online at https://lovd.euro-wabb.org.
KEYWORDS

Alström syndrome, genotype–phenotype analysis, locus-specific database, Monogenic diabetes,
Thiamine-responsive megaloblastic anemia syndrome, Wolfram syndrome
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INTRODUCTION

complex, and in common with other rare diseases, often subject to misdiagnosis, delayed diagnosis, and nondiagnosis. The syndromes exhibit

Monogenic diabetes syndromes are characterized by glucose intolerance together with extrapancreatic features, and result from one or
more defects in a single gene. There are about 40 different genetic
subtypes identified so far, with an estimated prevalence of 2%–5%
of all patients with diabetes (Schwitzgebel, 2014). The wide phenotypic and genetic heterogeneity poses significant problems for our
understanding of disease mechanisms, and for providing prognostic
information. This is compounded by the identification of diabetes
syndrome gene variants of uncertain significance, in isolated diabetes
through the widespread application of next-generation sequencing
(Alkorta-Aranburu et al., 2014; Ellard et al., 2013; Philippe et al.,
2015). There are no up-to-date variant databases for most monogenic
diabetes syndrome genes; those that do exist contain limited historical
variants on publicly available Websites (HGVS: http://www.hgvs.org/
dblist/dblist.html, GEN2PHEN: http://www.gen2phen.org/data/lsdbs,
LOVD: http://grenada.lumc.nl/LSDB_list/lsdbs, WAVe: http://bioin
formatics.ua.pt/WAVe, ClinVar: http://www.ncbi.nlm.nih.gov/clinvar).
Wolfram (type 1, MIM# 222300; type 2, MIM# 604928), Alström
(MIM# 203800), and Thiamine-responsive megaloblastic anemia
(MIM# 249270) syndromes are rare, monogenic syndromes where diabetes is a common feature. They are chronically debilitating, highly

clinical overlap: all can cause profound visual and hearing impairment,
and diabetes mellitus (DM) or impaired glucose tolerance. With 0.57,
0.14, and 0.1 cases per 100,000 (Prevalence of rare diseases: Bibliographic data, 2013), all three syndromes also fall within the EU rare
disease definition of “a prevalence of not more than 5 affected persons
per 10,000 population” (Regulation (EC) No 141/2000 of the European
Parliament, 2000).
Recommendations issued by the European Council in 2009 highlight the need for coordination and cooperation, and networking of
resources throughout Europe (The Council of the European Union,
2009). A number of projects including Orphanet, EUROPLAN, and
EURORDIS have made progress in this field. The EURO-WABB project
is an EU initiative to widen access to genetic testing, clinical information, and research for the overlapping rare diabetes syndromes
Wolfram, Alström, Bardet Biedl syndrome, and others, in Europe
(www.euro-wabb.org). As part of this project, we have created a new
locus-specific database to provide catalogs of gene variations involved
in monogenic diabetes syndromes. By building on the existing generic
frameworks and platforms for rare diseases, this gene variant database
operates at a disease-specific level to support efficient diagnosis and
research for these syndromic diabetes diseases.
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(Amr et al., 2007; Mozzillo et al., 2014; Rondinelli, Novara, Calcaterra,
Zuffardi, & Genovese, 2015).
Thiamine-responsive megaloblastic anemia syndrome (TRMA

This report focuses on four genes in the EURO-WABB locus-specific
database, namely ALMS1, WFS1, CISD2, and SLC19A2.

syndrome) is a rare autosomal-recessive condition characterized

Pathogenic variants in the gene ALMS1 (MIM# 606844) on chro-

by nonautoimmune DM (nontype 1), sensorineural hearing loss,

mosomes 2p13.1 have been identified in patients with Alström syn-

and megaloblastic anemia. The gene responsible, SLC19A2 (MIM#

drome (AS), an autosomal-recessive disease characterized by retinal

603941), is located on chromosome 1q24.2, consists of six exons with

dystrophy, childhood obesity, type 2 DM, and sensorineural hearing

497 amino acids spanning a 22.5-kb genomic region. It codes for a high

loss (Collin et al., 2002; Hearn et al., 2002; Marshall et al., 2005;

affinity thiamine transporter (Diaz, Banikazemi, Oishi, Desnick, & Gelb,

Marshall et al., 2007; Marshall et al., 2015). Other features include

1999; Dutta et al., 1999; Labay et al., 1999). Although anemia can be

dilated cardiomyopathy (70% of patients), hepatic diseases, and uro-

corrected by thiamine treatment, the hearing loss is progressive and

logical abnormalities (Alstrom, Hallgren, Nilsson, & Asander, 1959;

irreversible. In TRMA syndrome patients, DM and hearing loss can

Marshall et al., 2005; Marshall et al., 2007). ALMS1 consists of 23 exons

manifest from infancy to adolescence.

encompassing over 224 kb of genomic DNA encoding a centrosomal
protein of 4,169 amino acids, which contain a large tandem-repeat
domain consisting of 47 amino acids and has been implicated in the
assembly and maintenance of primary cilia (Hearn et al., 2005; Knorz
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et al., 2010; Li et al., 2007) and in fibrosis (Zulato et al., 2011).
Pathogenic variants in WFS1 (MIM# 606201) cause Wolfram syn-

We followed the guidelines for establishing locus-specific databases

drome (WS) type 1, a rare neurodegenerative disease characterized

(Celli, Dalgleish, Vihinen, Taschner, & den Dunnen, 2012; Vihinen, den

by DM and optic atrophy (OA). The gene is located on chromosome

Dunnen, Dalgleish, & Cotton, 2012). We formed a consortium of sci-

4p16.1, and codes for an 890 amino acid protein (Wolframin) con-

entists and clinicians working with these diseases through the EU-

sisting of eight exons spanning 33.4 kb of genomic DNA (Inoue et al.,

funded EURO-WABB European Registry project (Farmer et al., 2013).

1998). Wolframin is an endoplasmic reticulum (ER) membrane pro-

The database is based on the Leiden Open-source Variation Database

tein (Takeda et al., 2001), thought to function as ER calcium chan-

(LOVD) platform V2.0-36 (Fokkema et al., 2011) and stores both

nel or a regulator of ER calcium channel activity (Osman et al.,

published and submitted variants.

2003) and is involved in the unfolded protein response via inter-

Variations in the databases are named according to the HGVS

action with and regulation of the ER stress sensor ATF6𝛼 (Fonseca

nomenclature (Den Dunnen et al., 2016; http://varnomen.hgvs.org)

et al., 2010). It is under regulation by ER stress sensors PERK, IRE 1-

and include descriptions at DNA and protein levels. Variants are num-

alpha, and ATF6-beta (Fonseca et al., 2005; Odisho, Zhang, & Volchuk,

bered and described with respect to the NCBI reference sequences

2015).

NM_015120.4

(NP_055935.4),

NM_006005.3

(NP_005996.2),

WS type 1 is also known as DIDMOAD due to the clinical features

NM_001008388.4 (NP_001094344.1), NM_006996.2 (NP_008927.1)

associated with the disease (diabetes insipidus, diabetes mellitus, optic

for ALMS1, WFS1, CISD2, and SLC19A2, respectively, with +1 = A of

atrophy, and deafness). Although nonautoimmune insulin-dependent

ATG start codon. Previously published variants that do not conform

DM is the most common manifestation of WS, the most frequent cause

are renamed accordingly with the original description included in

of morbidity and mortality associated with the disease are neurologi-

the entry to facilitate cross-reference. Mutalyzer (Wildeman, van

cal disorders and urinary tract complications (Kinsley, Swift, Dumont,

Ophuizen, den Dunnen, & Taschner, 2008) is used to verify variant

& Swift, 1995).

description.

Pathogenic variants in the CISD2 gene (MIM# 611507) have been

We included the following minimum data item set: pathogenicity,

identified in patients with WS type 2 (Amr et al., 2007; Mozzillo et al.,

DNA change, genomic position in the reference sequence and genome

2014). WS type 2 differs from type 1 in respect that so far no diabetes

assembly (GRCh 38), predicted protein change, mutation type, variant

insipidus (DI) and psychiatric disorder has been associated with the dis-

remarks (other information available for the variant), technique used,

ease, and the novel presence of defective platelet aggregation leading

link to published reference if applicable, and the following anonymized

to peptic ulcer bleeding. CISD2 is located on chromosome 4q24, and

clinical data: ethnic origin, gender, consanguinity, and clinical features.

codes for a 135 amino acid protein ERIS (ER intermembrane small pro-

As standard for the LOVD system, the database has links to other ser-

tein), which consists of three exons spanning a 64.7-kb genomic region.

vices such as PubMed, HGNC, Entrez Gene, OMIM, and GeneCards, in

ERIS is a highly conserved zinc finger protein of the ER membrane

addition to sequence databases. The databases catalogs variants iden-

involved in the regulation of cellular calcium homeostasis and mito-

tified in patients reported to have been diagnosed with AS, WS type

chondrial biogenesis (Wang et al., 2014). Immunoprecipitation studies

1/type 2, and TRMA syndrome.

showed that ERIS protein coded by CISD2 does not interact with Wol-

In predicting variant pathogenicity, we followed guidelines from

fram protein (Amr et al., 2007). Studies in mice show that cisd2 defi-

the American College of Medical Genetics and Genomics (ACMG) and

ciency in these animals causes mitochondrial death and dysfunction

the Association of Molecular Pathology (AMP) (Richards et al., 2015)

accompanied by autophagic death (Chen et al., 2009). To date, only 13

and considered other supporting information such as experimen-

individuals with CISD2 mutations have been reported in the literature

tal evidence, presence in multiple families, segregation with disease
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TA B L E 1

Summary of the types of variants in ALMS1, WFS1, CISD2, and SLC19A2 database

Gene

ALMS1

WFS1

CISD2

SLC19A2

Chromosomal
location

2p13.1

4p16.1

4q24

1q24.2

Disease

Alström syndrome

Wolfram syndrome
type 1

Wolfram syndrome
type 2

Thiamineresponsive
megaloblastic
anemia (TRMA)
syndrome

Number of unique
variants

268

309

3

48
30

Substitutions

133

208

2

Deletions

90

64

1

13

Duplications

34

28

0

2

Insertions

7

5

0

1

Indels

3

4

0

2

Translocations

1

0

0

0

phenotypes, as well as the prediction algorithm SIFT (Ng & Hanikoff,

India, Korea, Melanesia). The gender of 194 patients is known and con-

2003), and PolyPhen-2 (Sunyaev et al., 2001).

sists of 109 males (56.2%) and 85 females (43.8%).

The database is implemented on a secure server held by University

The WFS1 database currently contain 309 unique variants iden-

of Melbourne, Australia, with only curators being able to modify

tified in 531 patients, including 23 previously unreported variants.

contents. All components of the server service are checked regularly

The frequency of WFS1 variant types consists of 67.3% (208/309)

to ensure the long-term integrity of the server and the information

substitutions, 20.7% (64/309) deletions, 9% (28/309) duplications,

stored in it (LSDB software, operating system, back-end database,

1.6% (5/309) insertions, and 1.3% (4/309) insertion/deletions. More

and Web server). Submitted variants are accepted and published after

than 50% (156/309) of WFS1 variants are missense variants, 19% are

curation. The databases are updated regularly, are publicly accessible

frameshifts (60/309), and 16.5% are nonsense changes (51/309). In-

(https://lovd.euro-wabb.org), and have been included in the Human

frame deletions, duplications, insertions, and indels made up 11.6%

Genome Variation Society (HGVS) list of locus-specific databases. The

(36/309) of the variants, and eight (2.6%) affect putative splice or

summary of the types of variants stored in the ALMS1, WFS1, CISD2,

regulatory sites. Of the missense variants in the database, 57%

and SLC19A2 databases are shown in Table 1.

(89/156) are predicted to be pathogenic, 32% (50/156) are likely

The ALMS1 database contains 268 unique variants, identified in

pathogenic, five (3%) are benign/likely benign, and 7.7% (12/156)

334 patients, including 17 previously unreported variants. The major-

are variants of uncertain significance. Twenty-nine of the missense

ity (49.6%; 133/268) are single-nucleotide substitutions, of which 104

variants are known to have an autosomal-dominant mode of inher-

(78%; 104/134) of the base substitutions lead to codon termination.

itance, 28 are involved in sensorineural hearing loss, and one vari-

Deletions make up 34% (90/268) of the total variants reported (83

ant (c.1385A>G; p.Glu462Gly) is associated with autosomal-dominant

frameshift, six nonsense, and one in-frame), with six variants having

congenital nuclear cataracts. Private variants (reported once or

deletions of more than 10 bases. The rest of the variants are duplica-

present in single family or small population) account for 43% (133/309)

tions (13%; 34/268), insertions (2.6%; 7/268), insertion/deletions or

of the total unique variants in the WFS1 database. The majority of the

indel (1%; 3/268), and translocations (1/268). The majority of vari-

variants reported (86%; 264/309) are located in exon 8. Most com-

ants are reported in exons 8 (51.5%; 137/268), 16 (17.3%; 46/268),

monly reported variants are c.1362_1377del (p.Tyr454*) reported 35

and 10 (16%; 43/268). The most frequently reported variant is the

times in 18 patients, c.1243_1245del (p.Val415del) reported 33 times

c.10775delC (p.Thr3592Lysfs6*) located in exon 16 that is reported

in 22 patients, and c.1230_1233del (p.Val412Serfs*29) reported 30

exclusively in 28 patients with English ancestry. Missense variants are

times in 26 patients. In 233 (44%) of WS patients in the database,

uncommon. Among the 24 missense variants in the ALMS1 database,

variants occur in the homozygous state.

11 (45.8%) are predicted to be pathogenic, four (16.7%) are likely

The geographic origin of WS patients reported includes Europe

pathogenic, four (16.7%) are benign or likely benign, and five (21%) are

(UK, Italy, Germany, France, Denmark, Spain, the Netherland, Finland,

variants of uncertain significance.

Hungary, Poland, Russia), Americas (USA, Canada Brazil), North Africa,

The geographic origin of reported AS patients includes Europe
(UK, Italy, Portugal, Sweden, Spain, France, Belgium, Germany, the

Middle East, and Asia (Lebanon, Iran, Iraq, Turkey, Japan, China, India,
Pakistan), and Australia.

Netherland, Norway, Serbia, Macedonia, Romania, Bulgaria, Slovakia,

To date, the CISD2 database contains three unique variants identi-

Yugoslavia, Poland, Ireland), North Africa (Morocco), the Americas

fied in 13 individuals, namely, c.109G>C (p.Glu37Gln), c.(103+1_104-

(US, Canada, Brazil, Argentina, the Caribbean), and Asia and Oceania

1)_(318+1_319-1)del, and c.103+1G>A. All result in exon deletion of

(Turkey, Israel, Iran, Iraq, Saudi Arabia, Lebanon, Japan, Taiwan, China,

CISD2 leading to early termination of the ERIS protein. The first CISD2
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mutation (c.109G>C, p.Glu37Gln) was identified in 10 family mem-

Italy. All novel variants identified were submitted to the EURO-WABB

bers of three consanguineous Jordanian families (Amr et al., 2007) who

database (https://lovd.euro-wabb.org).

presented with DM, sensorineural hearing loss, optic neuropathy, pep-

ALMS1:

six

nonsense

variants,

c.800G>A

(p.Trp267*),

tic ulcer, and defective platelet aggregation. The variant caused mis-

c.1011_1012del (p.Cys337*) in exon 5, c.4321C>T (p.Gln1441*),

sense changes in a conserved amino acid as well as aberrant splic-

c.6325G>T (p.Glu2109*), c.6532C>T (p.Gln2178*) in exon 8, and

ing resulting in the deletion of exon 2. Recently, two CISD2 mutations

c.9258dup (p.Asp3087*) in exon 10, have been identified. This report

have been identified in patients of Italian origin, the c.(103+1_104-

expands the spectrum of ALMS1 variants in exon 5 first described by

1)_(318+1_319-1)del and the c.103+1G>A, causing deletions of exon

Marshall et al. (2015). Nine novel variants causing frameshifts are pre-

2 and exon 1, respectively (Mozzillo et al., 2014; Rondinelli et al., 2015).

dicted to result in premature stop codon, and protein truncation have

The exon 2 deletion of CISD2 is predicted to abolish the transmem-

been identified in exon 8, intron 9, exon 10, and exon 18. Six frameshift

brane domain of the protein.

variants identified in exon 8 are: c.224dup (p.Thr742Asnfs*2),

Currently, there are 48 unique variants identified in 52 patients in

c.4025_4026delinsA (p.Gly1342Glufs*18), c.4053_4054del (p.His13

the SLC19A2 database. Most are substitutions (62.5%; 30/48) lead-

51Glnfs*5), c.4147_4150del (p.Ser1383Asnfs*19), c.5081del (p.Pro16

ing to missense (69%; 20/29) and early termination (27.6%; 8/29) of

92Leufs*39), and c.6901del (p.Val2301Trpfs*43). The c.(7677+

the SLC19A2 protein, with the possibility of transcript degradation

1_7678-1)_(10387+1_10388-1)del (p.Gly2560Serfs*46) identified in

via RNA-mediated decay. The rest of the variants are deletions (27%;

intron 9, a 362-bp deletion c.845brk6_8817del (p.Thr2819Argfs*29)

13/48), duplications (4.2%; 2/48), insertions, and indels (6.3%; 3/48)

was identified in exon 10 and c.11738dup (p.Ser3914Lysfs*6) was

causing frameshift and/or early termination of the SLC19A2 protein.

found in exon 18.

Among the 20 missense variants in the SLC19A2 database, 16 (80%) are

The significance of the missense variant c.3392C>G (p.Ala1131Gly)

predicted to be pathogenic, two (10%) likely pathogenic, and two (10%)

was unclear, although it is predicted to be probably damaging by

variants of uncertain significance. Most of the reported variants are in

the PolyPhen-2 algorithm. In the patient, this variant occurs in

exon 2 with c.697C>T (p.Gln233*) being the most commonly reported

the homozygous state together with a homozygous pathogenic

variant in TRMA patients originating from Iran and Turkey. From the

frameshift-causing deletion (c.(7677+1_7678-1)_(10387+1_10388-

82 patients reported with TRMA syndrome, 27 (33%) are of Middle

1)del; p.Gly2560Serfs*46). Homozygous missense variant c.4225G>A

Eastern origin, 24 (29%) have originated from the Mediterranean, and

(p.Val1409Ile; rs200529564) identified in exon 8 was likely benign,

14 (17%) are from South Asia.

as the patient also carries the homozygous novel pathogenic variant
c.5081del (p.Pro1692Leufs*39).
WFS1: twenty-three novel variants in the WFS1 gene have been

3.1 AS and WS patient recruitment and variant
identification

identified: two in intron 1, one in exon 4, and the rest are in exon 8

Children and adult patients with AS were recruited to the DAS

tion of the Wolframin protein, two are causing frameshift, three result

study (defining the phenotype in AS) (UKCRN 9044, REC approval

in in-frame deletions, nine are missense/nonsynonymous variants, and

10/H0203/33). Children with AS, and children and adults with WS,

two affect splice/regulatory regions.

(Table 3). Seven of these are nonsense variants causing early termina-

were recruited to the EURO-WABB European Registry study (UK

A novel homozygous nonsense variant c.334C>T; p.Gln112* was

REC approval 11/WM/0127). Appropriate informed consent was

identified in six individuals from five different families of Middle East-

obtained from adult patients and parents/guardians of children.

ern origin. Other novel nonsense variants identified are c.911_914dup;

Assent was also obtained where possible from children under 16

p.Met306*,

years. Clinical histories and medical records were obtained for all

c.2033G>A; p.Trp678*, c.2080G>T; p.Glu694*, c.2319C>G; p.Tyr773*,

participants.

and c.2425G>T; p.Glu809*. In addition to two novel frameshift

c.977C>T;

p.Ala326Val,

c.1944G>A;

p.Trp648*,

Genomic DNA were extracted from peripheral blood lympho-

variants, c.1434del; p.Trp478Cysfs*4 and c.958_962delinsTCC;

cytes using standard protocols. Sequencing of WFS1 and ALMS1

p.Pro320Serfs*39, we also identified three novel in-frame deletions

exons were performed using ABI 3730 automated sequencer

in our cohort: c.1529_1543del; p.Tyr510_Leu514del, c.1699_1704del;

(Applied Biosystems, Foster City, CA) after PCR amplifications.

p.Leu567_Phe568del, and c.1727_1744del; p.Gly576_Gly581del.

Identified variants were checked against dbSNP, 1000 Genomes

Novel missense variants p.Pro292Thr (c.874C>T; rs746923441),

Project, or ExAC (exac.broadinstitute.org) for the more recent

p.Pro428Arg (c.1283C>G), p.Ser446Arg (c.1338C>A), p.Pro533Ser

samples.

(c.1597C>T; rs146132083), and p.Tyr669Ser (c.2006A>C) are
predicted to be damaging/probably damaging by both SIFT and

3.2

Novel variants in ALMS1 and WFS1

PolyPhen-2, segregated with disease phenotypes, and are classified
as pathogenic. Four of the novel missense variants, p.Ala326Val

We report 17 novel germline ALMS1 variants detected in 17 UK AS

(c.977C>T), p.Glu385Lys (c.1153G>A; rs71524353), and p.Leu592Pro

patients from 16 families and one Slovakian patient (Table 2) and 23

(c.1775T>C) are predicted to be damaging/probably damaging by one

novel WFS1 variants in 59 UK WS patients from 48 families (Table 3)

of the prediction algorithms and are classified as likely pathogenic.

referred to the West Midlands Regional Genetic Service, Birmingham

The significance of p.Ile561Ser (c.1682T>G; rs776993839), predicted

Women’s Hospital and Department of Medicine, Padua University,

to be damaging by SIFT, is yet uncertain. In patient WSUK-45, who
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Patient

Location

Nucleotide changea

Protein change

Gender

Clinical findings

ALSUK1

Exon 8
Exon 8

c.4025_4026delinsA
c.6325G>T

p.(Gly1342Glufs*18)
p.(Glu2109*)

F

Severely impaired vision, hearing
difficulty requiring hearing aid,
heart defect (infancy), obesity
(infancy), raised creatinine (95
𝜇mol/L), bladder dysfunction, chest
infection, kyphoscoliosis.

ALSUK2

Exon 8
Exon 8

c.4053_4054del
c.4321C>T

p.(His1351Glnfs*5)
p.(Gln1441*)

M

Impaired vision (infancy), obesity
(infancy), global developmental
delay.

ALSUK3.1

Exon 8
Exon 8

c.4225G>A
c.4225G>A
c.5081del
c.5081del

p.(Val1409Ile)
p.(Val1409Ile)
p.(Pro1692Leufs*39)
p.(Pro1692Leufs*39)

M

Impaired vision (infancy), normal
hearing, obesity (infancy).

ALSUK3.2

Exon 8
Exon 8

c.4225G>A
c.4225G>A
c.5081del
c.5081del

p.(Val1409Ile)
p.(Val4091Ile)
p.(Pro1692Leufs*39)
p.(Pro1692Leufs*39)

M

Impaired vision (infancy), hearing
difficulty requiring hearing aid,
Fallots tetralogy, obesity.

ALSUK4

Exon 10
Exon 8

c.9258dup
c.5145T>G

p.(Asp3087*)
p.(Tyr1715*)

M

Cardiomyopathy.

ALSUK5

Exon 18
Exon 18

c.11738dup
c.11738dup

p.(Ser3914Lysfs*6)
p.(Ser3914Lysfs*6)

F

Impaired vision (severe), heart
abnormality (infancy), obesity
(infancy).

ALSUK6

Exon 19

c.11881dup

p.(Ser3961Phefs*12)

M

Photophobia and nystagmus (8 yr) but
not otherwise vision impaired,
cardiomyopathy, hyperlipidemia,
chronic renal failure, bladder
dysfunction.

ALSUK7

Exon 19

c.11881dup

p.(Ser3961Phefs*12)

M

Photophobia and nystagmus (8 yr) but
not otherwise vision impaired,
hearing difficulties requiring
cochlear implants, cardiomyopathy
(50 yr), left bundle branch block,
hyperlipidemia (55 yr), chronic renal
failure (55 yr), bladder dysfunction

ALSUK8

Exon 5
Exon 8

c.1011_1012del
c.6590del

p.(Cys337*)
p.(Lys2197Serfs*10)

M

Impaired vision (severe), hearing
difficulty requiring hearing aid,
heart defect (infancy), DM (18 yr),
NALFD, raised creatinine
(81𝜇mol/L).

ALSUK9

Exon 5
Exon 16

c.800G>A
c.11107C>T

p.(Trp267*)
p.(Arg3703*)

F

Impaired vision (infancy), normal
hearing, cardiomyopathy (infancy),
heart transplant then hemiparesis.

ALSUK10

Exon 8
Exon 16

c.2224dup
c.10975C>T

p.(Thr742Asnfs*2)
p.(Arg3703*)

F

Registered blind (1 yr), hearing
difficulty requiring hearing aid,
obesity (infancy), hyperlipidemia (18
yr), DM (18 yr).

ALSUK11

Exon 8
Exon 8

c.4147_4150del
c.4147_4150del

p.(Ser1383Asnfs*19)
p.(Ser1383Asnfs*19)

F

Impaired vision (infancy), obesity
(infancy), hyperlipidemia, DM (8 yr),
raised liver enzymes, microcephaly.

ALSUK12

Exon 8
Exon 8
Intron 9

c.3392C>G
c.3392C>G
c.(7677+1_76781)_(10387+1_103881)del

p.(Ala1131Gly)
p.(Ala1131Gly)
p.(Gly2560Serfs*46)

F

Impaired vision (severe), hearing
difficulty requiring hearing aid,
heart abnormality (infancy), obesity
(infancy), hyperlipidemia, NAFLD,
abnormal kidney function,
kyphoscoliosis, chronic chest
infections.

ALSUK13

Exon 8
Exon 8

c.6532C>T
c.11107C>T

p.(Gln2178*)
p.(Arg3703*)

M

Impaired vision (severe), hearing
difficulty requiring hearing aid,
heart defect (infancy), obesity
(infancy), DM (18 yr), NALFD, raised
creatinine (81 𝜇mol/L).

ALSUK14

Exon 8
Exon 8

c.6829C>T
c.9541C>T

p.(Arg2277*)
p.(Arg3181*)

M

Impaired vision (severe), obesity,
NAFLD
(Continues)
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Clinical findings

ALSUK15

Exon 8
Exon 8

c.6829C>T
c.9541C>T

p.(Arg2277*)
p.(Arg3181*)

F

Impaired vision (severe), hearing
difficulty (infancy) requiring hearing
aid, obesity (infancy), NAFLD,
bladder dysfunction,
gastro-esophageal reflux,
kyphoscoliosis.

ALSUK16

Exon 8
Exon 8

c.6901del
c.11449C>T

p.(Val2301Trpfs*43)
p.(Gln3817*)

M

Impaired vision (severe), hearing
difficulty (infancy) requiring hearing
aid, obesity (infancy),
hyperlipidemia, NAFLD, abnormal
kidney function, kyphoscoliosis (20
yr), hypogonadism.

SLO68-13

Exon 8
Exon 16

c.4156dupA
c.11207C>A

p.(Thr1386Asnfs*15)
p.(Ser3736*)

F

Impaired vision, obesity, impaired
glucose tolerance (13 yr), bilateral
macular hypoplasia, bilateral
cataract, microcrania, psychomotor
delay.

SLO301-11

Exon 10
Exon 10

c.8456_8817del
c.8456_8817del

p.(Thr2819Argfs*29)
p.(Thr2819Argfs*29)

F

Obesity, dilated cardiomyopathy, OA,
retinal dystrophy, sensorineural
hearing loss.

F, female; M, male; DM, diabetes mellitus; OA, optic atrophy; NAFLD, nonalcoholic fatty liver disease; yr, year.
Notes: Novel variants are in bold.
a
Nucleotide numbering: +1 is A of ATG start codon (NCBI Reference Sequence NM_015120.4).

presented with congenital hearing loss, childhood OA, and juvenile

Disease phenotype was classified as: (1) WS, defined by biallelic

DM, the p.Glu385Lys was present in a heterozygous state with no

inheritance of WFS1 variants and the presence of two major features

other WFS1 mutation. This patient also presented with an OPA1

(DM and OA) at any age of onset with/without other associated clinical

pathogenic mutation (duplication of exons 4–8) inherited from her

features (deafness, DI, neurological disorders), or the presence of one

mother and maternal grandfather. Both have OA with OPA1 and WFS1

major feature accompanied by at least two associated clinical features;

variants. Bonnycastle et al. (2013) identified a single-missense WFS1

(2) WFS1-related disorders (recessive form), defined by biallelic inher-

mutation (p.Trp314Arg) segregating with diabetes in a multigeneration

itance of WFS1 variants and the presence of one major feature (DM or

Finnish family. It is possible that the c.1153G>A; p.Glu385Lys also has

OA) with none or only one associated feature; and (3) WFS1-related

a dominant effect and is responsible for the diabetes phenotype in

disorders (dominant form), defined by dominant inheritance of a WFS1

our WSUK-45 patient. Although the patient’s mother also presented

variant and the presence of one or more clinical features (sensorineu-

with insulin-dependent diabetes, no information is available on the

ral deafness, DM, OA, DI, cataract).

diabetes status of the maternal grandfather to further support this

The patients’ genotypes were classified into two variant

claim. In our cohort, two families are also identified with a single non-

groups: group 1 are variants predicted to cause complete or

synonymous pathogenic WFS1 variant, interestingly both involving

partial loss of function (N-terminal nonsense and frameshifts,

substitution of amino acid glutamate to lysine (p.Glu385Lys and p.

splice-site variants predicted to cause exon skipping/deletions;

Glu864Lys).

C-terminal nonsense and frameshift; N-terminal small in-frame dele-

The effect of the novel intron 1 variants, the c.-6G>T substitu-

tions/duplications/insertions/indels); or compound heterozygous

tion, and the c. -184_-179dup duplication is not yet clear. Fibroblasts

where one variant is predicted to cause complete and the other

from the patient harboring this variant and a pathogenic c.937C>T;

a partial loss of function. Group 2 are variants predicted to cause

p.His313Tyr shows significant reduction of WFS1 expression in West-

minor loss of function (missense, C-terminal small in-frame dele-

ern blot analysis (data not shown). However, a single c.937C>T;

tions/duplications/insertions/indels) or compound heterozygous for

p.His313Tyr mutation has been shown to be capable of causing WS

a variant predicted to cause partial and minor loss of function (Supp.

(Hansen et al., 2005) and inducing ER stress (Bonnycastle et al.,

Table S1). We defined the WFS1 N-terminal as amino acids at positions

2013). One of our patients (WSUK-47) was also identified with the

1–652 (cytosolic and transmembrane domain) and the C-terminal as

p.His313Tyr variant without the presence of another pathogenic WFS1

amino acids at positions 653–890 (ER lumen) (Fig. 1).
Patients whose phenotype could clearly be identified were

variant.

then assigned into respective genotype and phenotype categories

3.3

WFS1 genotype–phenotype analysis

(Supp. Table S1). Vassar Stats Clinical Calculator 1 (vassarstats.net)
was used to estimate population prevalence, sensitivity, speci-

We collected information on the age of onset of DM, OA, deafness, DI,

ficity, predictive values, and likelihood ratios. The age of onset

and other reported clinical features from patients in the database and

of DM, OA, and DI between genotypic groups were compared

categorized the disease by phenotype and genotype.

using ANOVA. From 448 patients analyzed, 301 belonged to
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Patient/
ethnicity

Location

Nucleotide changea

Protein change

Gender

Clinical findings

WSUK-1

Exon 4

c.334C>T

p.(Gln112*)

M

DM 5 yr, OA 11 yr, hearing loss 8 yr, DI 26 yr,
learning difficulties.

Middle Eastern

Exon 4

c.334C>T

p.(Gln112*)

WSUK-2.1

Exon 8

c.1549delC

p.(Arg517Alafs*5)

F

DM, OA, DI, hearing loss.

Caucasian

Exon 8

c.2033G>A

p.(Trp678*)

WSUK-2.2

Exon 8

c.1549delC

Arg517Alafs

F

DM, OA, DI, hearing loss, psychiatric disorder.

Caucasian

Exon 8

c.2033G>A

p.(Trp678*)
M

DM 3 yr, OA 9 yr, hearing loss.

M

DM 5 yr, OA 23 yr, psychiatric problems.

M

DM, OA 8 yr, DI 11 yr, bladder dysfunction,
learning difficulties.

F

DM, OA, DI 7 yr.

F

DM 5 yr, OA 6 yr, hearing loss (all frequencies) 4
yr, DI 16 yr, bladder dysfunction.

F

OA (mild), hearing loss 5 yr, no DM.

F

DM 4 yr, OA, DI 4 yr, tinnitus.

F

DM, OA, DI, hearing loss, sleep apnea, weak
bones, learning difficulties.

F

DM 7 yr, OA 6 yr, DI, hearing loss, bladder
dysfunction, impaired renal function.

M

DM 13 yr, OA 15 yr, bladder dysfunction.

F

DM 5.5 yr, OA 5.5 yr, hearing loss 3.5 yr.

F

DM 13 yr, OA 13 yr, hearing loss (high
frequency), oral pharyngeal dysphasia,
bladder dysfunction, psychiatric disorder.

M

DM 4 yr, OA, DI, hearing loss, neuropathic
bladder.

M

DM 7 yr, OA 7 yr, neuropathic bladder,
psychiatric disorder.

F

DM 5 yr, OA, hearing loss (all freq.), ataxia,
psychiatric disorder.

F

DM, OA, bulbar palsy with recurrent choking
episodes, sleep apnea, bladder dysfunction,
cerebellar pontine hypoplasia.

WSUK-3.1

Exon 8

c.2146G>A

p.(Ala716Thr)

Caucasian

Exon 8

c.2648_2651del

p.(Phe883Serfs*68)

WSUK-3.2

Exon 8

c.2146GA

p.(Ala716Thr)

Caucasian

Exon 8

c.2648_2651del

p.(Phe883Serfs*68)

WSUK-4.1

Exon 8

c.1525_1539del

p.(Val509_Tyr513del)

Middle Eastern

c.1525_1539del

p.(Val509_Tyr513del)

WSUK-4.2

Exon 8

c.1525_1539del

p.(Val509_Tyr513del)

Middle Eastern

Exon 8

c.1525_1539del

p.(Val509_Tyr513del)

WSUK-5

Exon 8

c.911_914dup

p.(Met306*)

Caucasia

Exon 8

c.1994G>A

p.(Trp648*)

WSUK-6

Exon 8

c.2051C>T

p.(Ala684Val)

Caucasian

Exon 8

c.2452C>T

p.(Arg818Cys)

WSUK-7

Exon 5

c.505G>A

p.(Glu169Lys)

Caucasian

Exon 8

c.1558C>T

p.(Gln520*)

WSUK-8

Exon 4

c.334C>T

p.(Gln112*)

Middle Eastern

Exon 4

c.334C>T

p.(Gln112*)

WSUK-9

Exon 4

c.409_424dup

p.(Val142Glyfs*110)

Caucasian

Exon 8

c.2262_2263del

p.(Cys755Serfs*3)

WSUK-10

Exon 8

c.1504_1527dup

p.(Ser503_Val509dup)

Caucasian

Exon 8

c.2262_2263del

p.(Cys755Serfs*3)

WSUK-11

Exon 8

c.1338C>A

p.(Ser446Arg)

Caucasian

Exon 8

c.2327A>T

p.(Glu776Val)

WSUK-12

Exon 8

c.1283C>G

p.(Pro428Arg)

Caucasian

Exon 8

c.2319C>G

p.(Tyr773*)

WSUK-13.1

Exon 8

c.1401_1403del

p.(Leu468del)

Middle Eastern

Exon 8

c.1401_1403del

p.(Leu468del)

WSUK-13.2

Exon 8

c.1401_1403del

p.(Leu468del)

Middle Eastern

Exon 8

c.1401_1403del

p.(Leu468del)

WSUK-13.3

Exon 8

c.1401_1403del

p.(Leu468del)

Middle Eastern

Exon 8

c.1401_1403del

p.(Leu468del)

WSUK-14

Exon 8

c.906C>A

p.(Tyr302*)

Caucasian

Exon 8

c.2648_2651del

p.(Phe883Serfs*68)
(Continues)
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WSUK-15

Exon 8

c.2099G>A

p.(Trp700*)

M

DM 6 yr, OA 9 yr, DI, hearing loss (high
frequency), bladder dysfunction.

South European Exon 8

c.2099G>A

p.(Trp700*)

M

DM 14 yr, OA, DI, hearing loss (high frequency),
neurogenic bladder.

M

DM 2 yr, OA 20 yr, DI, hearing loss 6 yr,
neurogenic bladder, learning difficulties,
psychiatric disorder.

F

DM 3 yr, OA 11 yr, hearing loss (high frequency,
mild).

F

DM 8 yr, OA 34 yr, hearing loss 26 yr, bladder
dysfunction.

M

DM 4 yr, OA 9 yr, DI 24 yr, deteriorating balance
and mobility, choking episodes, psychiatric
disorder.

M

DM 5 yr, OA 11 yr, DI 20 yr, psychiatric disorder.

F

DM 6 yr, OA, DI, bladder dysfunction,
psychiatric disorder (mild).

F

DM 3yr, OA 5 yr, DI 8 yr, hearing loss, ataxia,
chronic fatigue syndrome, psychiatric
disorders.

M

DM 11 yr, OA 12 yr, DI, hearing loss 13 yr,
bladder dysfunction, cerebellar signs.

F

DM 11 yr, OA 12 yr, DI, hearing loss 13 yr.

F

DM 10 yr, OA 11 yr, DI, bladder dysfunction,
delayed puberty, pharyngeal dysphasia,
cerebellar dysfunction.

M

DM 13 yr, DI 16 yr, bladder dysfunction.

F

DM, OA, DI

F

DM 5 yr, poor night vision, DI, hearing loss 15 yr,
bilateral cataract, microalbuminuria,
cerebellar signs (mild).

F

DM, OA, DI, hearing loss 7 yr, congenital
hypothyroidism, diabetic retinopathy,
neuropathic bladder, psychiatric disorder.

M

DM 4 yr, OA, DI, diabetic retinopathy, mild
ataxia, microcephaly.
(Continues)

Exon 8
WSUK-16

Exon 5

c.505G>A

p.(Glu169Lys)

Caucasian

Exon 8

c.874C>A

p.(Pro292Thr)

WSUK-17

Exon 4

c.334C>T

p.(Gln112*)

Middle Eastern

Exon 4

c.334C>T

p.(Gln112*)

WSUK-18

Exon 8

c.2002C>T

p.(Gln668*)

Caucasian

Exon 8

c.2080G>T

p.(Glu694*)

WSUK-19

Exon 8

c.1727_1744del

p.(Gly576_Gly581del)

Middle Eastern

Exon 8

c.1727_1744del

p.(Gly576_Gly581del)

WSUK-20.1

Exon 8

c.2654C>T

p.(Pro885Leu)

Middle Eastern

Exon 8

c.2654C>T

p.(Pro885Leu)

WSUK-20.2

Exon 8

c.2654C>T

p.(Pro885Leu)

Middle Eastern

Exon 8

c.2654C>T

p.(Pro885Leu)

WSUK-21

Exon 8

c.1434del

p.(Trp478Cysfs*4)

Caucasian

Exon 8

c.2425G>T

p.(Glu809*)

WSUK-22

Exon 8

c.1549C>T

p.(Arg517Cys)

Caucasian

Exon 8

c.1682T>G

p.(Ile561Ser)

Exon 8

c.1775T>C

p.(Leu592Pro)

Exon 8

c.1944G>A

p.(Trp648*)

WSUK-23.1b

Exon 5

c.505G>A

p.(Glu169Lys)

Caucasian

Exon 7

c.817G>T

p.(Glu273*)

WSUK-23.2b

Exon 5

c.505G>A

p.(Glu169Lys)

Caucasian

Exon 7

c.817G>T

p.(Glu273*)

WSUK-24

Exon 8

c.1433G>A

p.(Trp478*)

Caucasian

Exon 8

c.2648_2651del

p.(Phe883Serfs*68)

WSUK-25

Exon 8

c.1049_1051del

p.(Phe350del)

Caucasian

Exon 8

c.2206G>A

p.(Gly736Ser)

WSUK-26

Exon 8

c.1309G>C

p.(Gly437Arg)

Caucasian

Exon 8

c.1434del

p.(Trp478Cysfs*4)

WSUK-27

Exon 8

c.1230_1233del

p.(Val412Serfs*29)

Caucasian

Exon 8

c.1243_1245del

p.(Val415del)

WSUK-28.1

Exon 8

c.2006A>C

p.(Tyr669Ser)

Caucasian

Exon 8

c.2006A>C

p.(Tyr669Ser)

WSUK-28.2

Exon 8

c.2006A>C

p.(Tyr669Ser)
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Caucasian

Exon 8

c.2006A>C

p.(Tyr669Ser)

WSUK-29

Exon 8

c.2099G>A

p.(Trp700*)

South European Exon 8

c.2099G>A

p.(Trp700*)

WSUK-30

c.1096C>T

p.(Gln366*)

South European Exon 8

c.1672C>T

p.(Arg558Cys)

WSUK-31.1

Exon 4

c.334C>T

p.(Gln112*)

Middle Eastern

Exon 4

c.334C>T

p.(Gln112*)

WSUK-31.2

Exon 4

c.334C>T

p.(Gln112*)

Middle Eastern

Exon 4

c.334C>T

p.(Gln112*)

Exon 8

Nucleotide changea

Protein change

WSUK-32.1

Exon 8

c.2643_2646del

p.(Phe882Serfs*69)

Middle Eastern

Exon 8

c.2643_2646del

p.(Phe882Serfs*69)

WSUK-32.2

Exon 8

c.2643_2646del

p.(Phe882Serfs*69)

Middle Eastern

Exon 8

c.2643_2646del

p.(Phe882Serfs*69)

WSUK-33

Exon 8

c.958_961delinsTCC

p.(Pro320Serfs*39)

Middle Eastern

Exon 8

c.958_961delinsTCC

p.(Pro320Serfs*39)

WSUK-34

Exon 4

c.334C>T

p.(Gln112*)

Middle Eastern

Exon 4

c.334C>T

p.(Gln112*)

WSUK-35

Exon 8

c.2099G>A

p.(Trp700*)

South European Exon 8

c.2099G>A

p.(Trp700*)

WSUK-36.1

c.1549del

p.(Arg517Alafs*5)

Exon 8

Caucasian

Exon 8

c.1597C>T

p.(Pro533Ser)

WSUK-36.2

Exon 8

c.1549del

p.(Arg517Alafs*5)

Caucasian

Exon 8

c.1597C>T

p.(Pro533Ser)

WSUK-37

Exon 8

c.1309G>C

p.(Gly437Arg)

Caucasian

Exon 8

c.1699_1704del

p.(Leu567_Phe568del)

WSUK-38

Exon 5

c.605A>G

p.(Glu202Gly)

Caucasian

Exon 7

c.817G>T

p.(Glu273*)

WSUK-39

Exon 7

c.817G>T

p.(Glu273*)

Caucasian

Exon 8

c.1504_1527dup

p.(Ser502_Val509dup)

WSUK-40

Exon 4

c.376G>A

p.(Ala126Thr)

Caucasian

Exon 8

c.1885C>T

p.(Arg629Trp)

WSUK-41

Exon 8

c.1529_1543del

p.(Tyr510_Leu514del)

Caucasian

Exon 8

c.2254G>T

p.(Glu752*)

WSUK-42

Exon 8

c.2648_2651del

p.(Phe883Serfs*68)

Caucasian

Exon 8

c.2648_2651del

p.(Phe883Serfs*68)

WSUK-43

Exon 8

c.2648_2651del

p.(Phe883Serfs*68)

Caucasian

Intron 1

c. -6G>T

p.?

WSUK-44

Exon 8

c.937C>T

p.(His313Tyr)

Middle Eastern

Intron 1

c.-184_179dupTGCCCC

p.?

WSUK-45

Exon 8

c.1153G>Ac

p.(Glu385Lys)

Gender

Clinical findings

M

DM, OA, hearing loss (high frequency).

F

DM, OA

F

p.(Gln112*)

M

DM 7 yr, OA 9 yr, coeliac disease, resting hand
tremors.

F

DM 4.5 yr, OA 9 yr, DI 13 yr.

M

DM 2.5 yr, bladder dysfunction.

M

DM, OA, hearing loss, bladder dysfunction,
primary testicular atrophy, psychiatric
disorder.

M

DM, OA, DI

F

DM 4 yr, OA 7 yr

F

OA, hearing loss, neurogenic bladder,
autonomic dysfunction.

M

OA, hearing loss (high frequency), urinary
urgency, erectile dysfunction, restless leg
syndrome.

F

DM 8 yr, OA 22 yr, hearing loss, bladder
dysfunction, ataxia, psychiatric disorder.

F

DM 14 yr, OA 14 yr, neurogenic bladder.

M

DM 7 yr, OA 7 yr, DI 8 yr, hearing loss (high
frequency) 6 yr, bladder dysfunction.

M

DM 10 yr, OA 8 yr, hearing loss (high freq.) 11 yr,
psychiatric disorder.

M

DM 2 yr, OA 7 yr, DI, mild cerebellar
dysfunction.

F

DM 10 yr.

F

DM 11 yr, OA 10 yr, learning difficulties,
reduced white matter on MRI brain scan.

M

DM 1.5 yr, OA (mild), congenital hearing loss.

F

DM 9 yr, OA 4 yr, congenital hearing loss.
(Continues)
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(Continued)
Location

Nucleotide changea

Protein change

Gender

Exon 8

c.2590G>Ac

p.(Glu864Lys)

M

Exon 8

c.937C>Tc

p.(His313Tyr)

F

OA, DM, hearing loss, short stature

WSUK-48

Exon 8

c.977C>T

p.(Ala326Val)

F

OA, DM

Caucasian

Exon 8

c.1309G>C

p.(Gly437Arg)

Clinical findings

Caucasian
WSUK-46
Caucasian
WSUK-47

OA 10 yr, congenital hearing loss.

Caucasian

F, female; M, male; DM, diabetes mellitus; OA, optic atrophy; DI, diabetes insipidus; yr, year.
Notes: Novel variants are in bold.
a
Nucleotide numbering: +1 is A of ATG start codon (NCBI Reference Sequence NM_006005.3).
b
Twin.
c
Only heterozygous variant identified.

F I G U R E 1 WFS1 variant distribution based on disease phenotype. Position of the amino acid involved in the disease phenotype is indicated by
different shades. Position of the transmembrane regions were predicted based on TMHMM (Krogh, Larsson, von Heijne, & Sonnhammer, 2001)
and SMART (Letunic, Doerks, & Bork, 2015). ER, endoplasmic reticulum

TA B L E 4

Number of patient classified according to genotype and phenotype

Phenotype

Group 1

Group 2

Total

Wolfram syndrome

295

78

373

WFS1-related disorders (recessive form)

6

8

14

WFS1-related disorders (dominant form)

0

61

61

Total

301

147

448

Notes: Group 1: variants predicted to cause complete or partial loss of function (N-terminal nonsense and frameshifts, splice-site variants predicted to cause
exon skipping/deletions; C-terminal nonsense and frameshift; N-terminal small in-frame deletions/duplications/insertions/indels); or compound heterozygous where one variant is predicted to cause complete and the other a partial loss of function.
Group 2: variants predicted to cause minor loss of function (missense, C-terminal small in-frame deletions/duplications/insertions/indels) or compound heterozygous for a variant predicted to cause partial and minor loss of function. See Supp. Table S1 for detail.

group 1 and 147 to group 2 genotypes. In patients with group

95%–99%. The classification of a group 2 genotype has a modest sen-

1 genotype, 295 have the WS phenotype and six have a reces-

sitivity (30%–81%) and specificity (63%–72%) in predicting recessive

sive form of WFS1-related disorder. In patients with group 2

WFS1-related disorders; however, it has high sensitivity (93%–100%)

genotype, 78 have WS phenotype, eight have recessive forms of

and specificity (73%–82%) in predicting the dominant form of WFS1-

WFS1-related disorders, and 61 patients presented with dominant

related disorders (Table 5). Six of the patients harboring group 1

forms of WFS1-related disorders (Table 4). The classification of a group

genotypes presented without a classic WS phenotypes (no reported

1 genotype is highly sensitive (75%–83%) and specific (83%–97%)

OA at adulthood or during data collection). Four of these patients are

in predicting a WS phenotype with a positive predictive value of

brothers from a Latin American family and two are from different

775

ASTUTI ET AL .

TA B L E 5

Sensitivity and specificity of WFS1 genotype to predict phenotype

Phenotype

Genotype

Wolfram syndrome

Sensitivity
(95% CI)

Specificity
(95% CI)

Positive predictive
value (95% CI)

Negative predictive
value (95% CI)

Group 1

79 (75, 83)

92 (83, 97)

98 (95, 99)

47 (39, 55)

Group 2

21 (17, 25)

8 (3, 17)

53 (45, 61)

2 (1, 5)

WFS1-related disorders
(recessive form)

Group 1

43 (19, 70)

32 (28, 37)

2 (1, 5)

95 (89, 97)

Group 2

57 (30,81)

68 (63, 72)

5 (3, 11)

98 (95, 99)

WFS1-related disorders
(dominant form)

Group 1

0 (0, 7)

22 (18, 27)

0 (0, 2)

58 (50, 66)

Group 2

100 (93, 100)

78 (73, 82)

42 (34, 50)

100 (98, 100)

CI, confidence interval.
Notes: Group 1: variants predicted to cause complete or partial loss of function (N-terminal nonsense and frameshifts, splice-site variants predicted to cause
exon skipping/deletions; C-terminal nonsense and frameshift; N-terminal small in-frame deletions/duplications/insertions/indels); or compound heterozygous where one variant is predicted to cause complete and the other a partial loss of function.
Group 2: variants predicted to cause minor loss of function (missense, C-terminal small in-frame deletions/duplications/insertions/indels) or compound heterozygous for a variant predicted to cause partial and minor loss of function.
Sensitivity, specificity, positive predictive value, and negative predictive value was calculated using VassarStats Clinical calculator 1 (www.vassarstats.net).

TA B L E 6

Age of onset of diabetes mellitus, optic atrophy, hearing loss, and diabetes insipidus based on genotype classification

Genotype

Diabetes mellitus
(Mean ± SD)

Optic atrophy
(Mean ± SD)

Deafness
(Mean ± SD)

Diabetes insipidus
(Mean ± SD)

Group 1

6.3 ± 3.5 years

11.7 ± 5.7 years

14.4 ± 7.2 years

13.9 ± 6.7 years

n = 300

n = 249

n = 142

n = 114

12.0 ± 9.9 years

15.8 ± 11.4 years

18.0 ± 13.7 years

18.0 ± 10.2 years

n = 90

n = 81

n = 37

n = 29

<0.0001

0.0021

0.125

0.047

Group 2

P (t-test)

Notes: Group 1: variants predicted to cause complete or partial loss of function (N-terminal nonsense and frameshifts, splice-site variants predicted to cause
exon skipping/deletions; C-terminal nonsense and frameshift; N-terminal small in-frame deletions/duplications/insertions/indels); or compound heterozygous where one variant is predicted to cause complete and the other a partial loss of function.
Group 2: variants predicted to cause minor loss of function (missense, C-terminal small in-frame deletions/duplications/insertions/indels) or compound heterozygous for a variant predicted to cause partial and minor loss of function.

UK-White European families. In these cases, we speculate that

a delayed onset of OA (Zalloua et al., 2008). We therefore ana-

genetic and environmental interactions may contribute to variable

lyzed 19 patients carrying homozygous frameshift variants in the C-

expressivity.

terminal of WFS1 (patients 265, 271–280, 285, 290, 295–298, 300,

Comparison of the age of onset of DM and OA in group 1 and

and 301 in Supp. Table S1), and 33 patients harboring a homozy-

group 2 genotypes revealed a highly significant difference in pheno-

gous frameshift variant in the N-terminal region (patients 14–21, 58,

types between the two groups. The mean age of onset of DM was

63, 87–91, 104, 112, 116, 118, 119, 123, 135, 198, 202, 235, 243–

6.3 ± 3.5 years in patients with group 1 genotypes and 12.0 ± 9.9 years

247, and 252–254 in Supp. Table S1). There is a slight difference

in individuals with group 2 genotypes (P < 0.0001), whereas the mean

in the age of onset of OA in patients with homozygous frameshift

age of onset of OA was 11.7 ± 5.7 years in individuals with group 1

C-terminal variant compared with the age of OA onset in patients

genotypes and 15.8 ±11.4 years in individuals carrying group 2 geno-

with homozygous frameshift N-terminal variants (13.2 ± 5 years

types (P = 0.0023). A significant difference in the age of onset of DI

and 11.2 ± 6.1 years, respectively). However, this is not statistically

was also observed between individuals carrying group 1 and group 2

significant. Variants associated with a WS phenotype were distributed

genotypes. The mean age of onset of DI was 13.9 ± 6 years and 18.0 ±

in both outside and inside the transmembrane region, whereas variants

10 years in group 1 and group 2 genotypes (P = 0.047), respectively

involved in the dominant form of WFS1-related disorder were mainly

(Table 6). Rohayem et al. (2011) and de Heredia, Clèries, and Nunes

located at the C-terminal end of the protein (Fig. 1).

(2013) also showed significant differences in the age of onset of
DM and DI among patients carrying predicted complete, partial,
or minor loss-of-function mutation. However, due to differences in

3.4

Future prospects and database update

genotypic classification used by these authors, the mean age of

The clinical overlaps and complexity exhibited by the syndromes men-

onset of DM and DI cannot be directly compared. It has been

tioned in this report may lead to delayed or misdiagnosis. We have

previously reported that some patients harboring a homozygous

demonstrated that a more detailed description of clinical phenotypes

frameshift variant in the C-terminal end of WFS1 tend to have

in the patients coupled with genotype information can provide insight
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into genotype–phenotype correlations of these syndromes. Unfortunately, the clinical phenotypes are difficult to access, not always available, and can be unreliable sometimes in terms of age of onset. We
hope that the information available for some of the patients in our
databases will allow for better understanding of the disease and reliable genetic counselling for the patients and their families. Ultimately,
functional studies of the variants will be necessary to further our
understanding of disease mechanisms that will lead to the development of personalized therapies.
The

EURO-WABB

LOVD

locus-specific

databases

for

ALMS1/WFS1/CISD2/ SLC19A2 have been available online since
2012 and have received submissions of variants identified in patients.
Future contributors can submit their variants online or by contacting and providing curators with the necessary information. When
referring to the EURO-WABB ALMS1/WFS1/CISD2/ SLC19A2 LOVD
databases, we kindly ask users to cite this article.
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